Amgen Inc. $AMGN Stock Acquired by International Assets Investment Management LLC

Key Points

• International Assets Investment Management increased its Amgen stake by 1,105.8% in the third quarter, holding 46,000 shares valued at approximately $19.4 million. Institutional investors collectively own 76.5% of the company.
• Amgen shares opened at $466.01, near their 12-month high of $475.65, while the company announced a quarterly dividend of $2.52 per share, representing a 2.2% annualized yield.
• Analysts maintain a consensus “Hold” rating with a $389.71 price target. Investors are weighing Amgen’s strong earnings and pipeline progress against rising expenses, MariTide development costs and execution risks ahead of its next results.

International Assets Investment Management LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 1,105.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,000 shares of the medical research company's stock after purchasing an additional 42,185 shares during the period. International Assets Investment Management LLC's holdings in Amgen were worth $19,389,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rational Advisors Inc. boosted its holdings in Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company's stock worth $72,000 after buying an additional 24 shares during the last quarter. Beacon Financial Advisory LLC raised its holdings in shares of Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company's stock valued at $461,000 after acquiring an additional 25 shares during the last quarter. James T. Borello RIA raised its holdings in shares of Amgen by 13.6% during the third quarter. James T. Borello RIA now owns 209 shares of the medical research company's stock valued at $88,000 after acquiring an additional 25 shares during the last quarter. Sweeney & Michel LLC raised its holdings in shares of Amgen by 0.5% during the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company's stock valued at $2,162,000 after acquiring an additional 25 shares during the last quarter. Finally, Legacy Financial Advisors Inc. lifted its position in shares of Amgen by 0.8% in the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company's stock valued at $1,234,000 after acquiring an additional 26 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Amgen Stock Up 1.1%

AMGN stock opened at $466.01 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a 50-day moving average of $419.96 and a two-hundred day moving average of $374.79. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $475.65. The company has a market cap of $251.94 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 3.37 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts forecast that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Argus lifted their price target on Amgen from $375.00 to $460.00 and gave the stock a "buy" rating in a research note on Wednesday, August 19th. Oppenheimer reiterated an "outperform" rating on shares of Amgen in a research report on Friday, October 23rd. Mizuho increased their price objective on Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a research note on Tuesday, August 18th. HSBC lowered Amgen from a "buy" rating to a "hold" rating and decreased their price objective for the company from $445.00 to $425.00 in a report on Thursday, September 10th. Finally, TD Cowen lifted their target price on shares of Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of "Hold" and a consensus price target of $389.71.

Insider Buying and Selling

In related news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.